These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6260109)

  • 21. Reduction of misonidazole and its derivatives by xanthine oxidase.
    Josephy PD; Palcic B; Skarsgard LD
    Biochem Pharmacol; 1981 Apr; 30(8):849-53. PubMed ID: 6894696
    [No Abstract]   [Full Text] [Related]  

  • 22. No significant effect of metoclopramide on misonidazole elimination in man.
    Williams KM; Begg EJ; Wade DN; O'Shea K
    Br J Clin Pharmacol; 1983 Mar; 15(3):390-2. PubMed ID: 6849772
    [No Abstract]   [Full Text] [Related]  

  • 23. Polarographic measurement of misonidazole in mouse mammary tumors.
    Ohizumi Y; Maezawa H; Murayama C; Mori T
    Tokai J Exp Clin Med; 1984 Aug; 9(3):199-206. PubMed ID: 6537667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Causes of apparent low levels of misonidazole in human tumours.
    Ash DV; Smith MR
    Clin Radiol; 1980 Mar; 31(2):233-7. PubMed ID: 7363558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutathione conjugates of misonidazole.
    Varghese AJ
    Biochem Biophys Res Commun; 1983 May; 112(3):1013-20. PubMed ID: 6847675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of a reactive metabolite of misonidazole in hypoxic mammalian cells.
    Varghese AJ; Whitmore GF
    Radiat Res; 1984 Feb; 97(2):262-71. PubMed ID: 6538047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers.
    Koch CJ; Giandomenico AR; Iyengar CW
    Biochem Pharmacol; 1993 Sep; 46(6):1029-36. PubMed ID: 8216345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absorption and distribution of vaginally administered misonidazole.
    Ash D; Bugden R; Calvert R
    Cancer Chemother Pharmacol; 1982; 9(2):118-9. PubMed ID: 7172406
    [No Abstract]   [Full Text] [Related]  

  • 29. Acetamide--a metabolite of metronidazole formed by the intestinal flora.
    Koch RL; Chrystal EJ; Beaulieu BB; Goldman P
    Biochem Pharmacol; 1979 Dec; 28(24):3611-5. PubMed ID: 231450
    [No Abstract]   [Full Text] [Related]  

  • 30. No significant effect of cimetidine on the pharmacokinetics of misonidazole in man.
    Begg EJ; Williams KM; Wade DN; O'Shea KF
    Br J Clin Pharmacol; 1983 May; 15(5):575-6. PubMed ID: 6860535
    [No Abstract]   [Full Text] [Related]  

  • 31. Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.
    Moore JL; Paterson IC; Newman H; Venables S
    Br J Cancer; 1981 Oct; 44(4):592-6. PubMed ID: 7295516
    [No Abstract]   [Full Text] [Related]  

  • 32. Binding of nitroreduction products of misonidazole to nucleic acids and protein.
    Varghese AJ; Whitmore GF
    Cancer Clin Trials; 1980; 3(1):43-6. PubMed ID: 7389036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative misonidazole metabolism in anaerobic bacteria and hypoxic Chinese hamster lung fibroblast (V-79-473) cells.
    Koch RL; Rose C; Rich TA; Goldman P
    Biochem Pharmacol; 1982 Feb; 31(3):411-4. PubMed ID: 7073768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A drug for improved radiosensitization in radiotherapy.
    Dische S; Fowler JF; Saunders MI; Stratford MR; Anderson P; Minchinton AI; Lee ME
    Br J Cancer; 1980 Jul; 42(1):153-5. PubMed ID: 7426325
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of cimetidine, antipyrine, and pregnenolone carbonitrile on misonidazole pharmacokinetics.
    Workman P; Donaldson J; Smith NC
    Cancer Treat Rep; 1983; 67(7-8):723-5. PubMed ID: 6871889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mechanism of binding of the radiosensitizers metronidazole and misonidazole (Ro-07-0582) to bovine and human serum albumin--a proton NMR study.
    SuĊ‚kowska A; Lubas B; Wilczok T
    Radiat Res; 1981 Jan; 85(1):1-12. PubMed ID: 7465767
    [No Abstract]   [Full Text] [Related]  

  • 37. In situ drug delivery.
    Levin VA; Wright DC; Landahl HD; Patlak CS; Csejtey J
    Br J Cancer Suppl; 1980 Apr; 4():74-8. PubMed ID: 6932949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of misonidazole by rat liver microsomes and purified NADPH-cytochrome c reductase.
    McManus ME; Lang MA; Stuart K; Strong J
    Biochem Pharmacol; 1982 Feb; 31(4):547-52. PubMed ID: 6802140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination.
    Williams K; Begg E; Wade D; O'Shea K
    Clin Pharmacol Ther; 1983 Mar; 33(3):314-21. PubMed ID: 6825387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic properties of hydroxylamino- and amino-misonidazole, possible metabolic products of misonidazole, in hypoxic HeLa S3 cells.
    Murayama C; Hori H; Mori T; Inayama S
    Gan; 1983 Oct; 74(5):693-8. PubMed ID: 6642142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.